U.S. markets closed

Shattuck Labs, Inc. (STTK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
41.25-0.50 (-1.20%)
At close: 4:00PM EST

41.25 0.00 (0.00%)
After hours: 4:01PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close41.75
Open41.70
Bid40.92 x 800
Ask46.84 x 800
Day's Range38.88 - 41.80
52 Week Range17.51 - 60.52
Volume82,375
Avg. Volume189,235
Market Cap1.722B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est54.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Shattuck Labs Announces Participation in Upcoming March Investor Conferences
      GlobeNewswire

      Shattuck Labs Announces Participation in Upcoming March Investor Conferences

      AUSTIN, TX and DURHAM, NC, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that Shattuck management will participate in two upcoming investor conferences. Presentation DetailsConference: Cowen 41st Annual Health Care ConferenceFormat: Ovarian Cancer Panel discussion Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer Date: March 2, 2021Time: 12:50 p.m. ESTWebcast Link: The panel discussion will be available live to conference attendees Conference: Oppenheimer 31st Annual Healthcare ConferencePresenter: Andrew Neill, Shattuck’s Vice President of Finance and Corporate StrategyDate: March 16, 2021Time: 11:20 a.m. ESTWebcast Link: Available Here The live webcast of the Oppenheimer presentation will be available on the Events & Presentations section of the Company’s website. A replay of the webcast will be archived for up to 90 days following the presentation date. About Shattuck Labs, Inc.Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com. Investor Contact: Conor RichardsonSenior Director, Finance & Investor RelationsShattuck Labs, Inc.InvestorRelations@shattucklabs.com Media Contact:Stephanie Ascher Managing DirectorStern Investor Relations, Inc.Stephanie.ascher@sternir.com

    • Shattuck Labs Announces Participation in Citi’s 2021 Virtual Immuno-Oncology Day
      GlobeNewswire

      Shattuck Labs Announces Participation in Citi’s 2021 Virtual Immuno-Oncology Day

      AUSTIN, TX & DURHAM, NC, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in Citi’s 2021 Virtual Immuno-Oncology Day Conference being held virtually February 17-18, 2021. Presentation DetailsConference: Citi 2021 Virtual Immuno-Oncology DayFormat: Group meeting with Andrew Baum and covering analyst Mohit BansalPresenters: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer and Andrew Neill, Shattuck’s Vice President of Finance and Corporate StrategyDate: February 17, 2021Time: 12:00 p.m. ESTWebcast Link: Available Here A live webcast will be available at the Events & Presentations section of the Company’s website. About Shattuck Labs, Inc.Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com. Investor Contact:Conor RichardsonSenior Director, Finance & Investor RelationsShattuck Labs, Inc.InvestorRelations@shattucklabs.com Media Contact:Stephanie AscherManaging DirectorStern Investor Relations, Inc.Stephanie.ascher@sternir.com

    • Shattuck Labs (NASDAQ:STTK) Is In A Good Position To Deliver On Growth Plans
      Simply Wall St.

      Shattuck Labs (NASDAQ:STTK) Is In A Good Position To Deliver On Growth Plans

      Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...